semaglutide drug shortage ends as FDA sets deadline for compounders US judge upholds FDA's removal

Sex-disaggregated data were not consistently available at the trial arm level and were therefore not included in the analysis

New-to-GLP-1 patients are required to start on a three-month bundle, which drops the per-month cost further

1 2 "Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee"

It is sometimes used off-label for purported anti-aging purposes, body composition improvement, and metabolic enhancement, though it lacks FDA approval for these indications

No guesswork, no squinting at half-unit marks

doi: 10.1007/s11064-015-1824-6 70 NiheiWKatoAHimenoTKondoMNakamuraJKamiyaHet al